Acorda Therapeutics Inc. (NASDAQ: ACOR) started the day on September 15, 2020, with a price increase of 12.54% at $0.51. During the day, the stock rose to $0.5455 and sunk to $0.446 before settling in for the price of $0.45 at the close. Taking a more long-term approach, ACOR posted a 52-week range of $0.42-$4.04.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -13.70%. Meanwhile, its Annual Earning per share during the time was 16.45%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 4.70%. This publicly-traded company’s shares outstanding now amounts to $47.71 million, simultaneously with a float of $47.18 million. The organization now has a market capitalization sitting at $25.71 million. At the time of writing, stock’s 50-day Moving Average stood at $0.6410, while the 200-day Moving Average is $1.1628.
Let’s gauge the efficiency of the firm, which has a total of 344 employees. It has generated 559,326 per worker during the last fiscal year. Meanwhile, its income per employee was -793,506. The stock had 8.46 Receivables turnover and 0.17 Total Asset turnover. For the Profitability, stocks gross margin was +68.56, operating margin was -60.60 and Pretax Margin of -142.53.
Acorda Therapeutics Inc. (ACOR) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Acorda Therapeutics Inc.’s current insider ownership accounts for 1.49%, in contrast to 61.20% institutional ownership. According to the most recent insider trade that took place on Dec 02, this organization’s President, Intl and GC sold 2,227 shares at the rate of 1.60, making the entire transaction reach 3,553 in total value, affecting insider ownership by 117,420. Preceding that transaction, on Dec 02, Company’s Chief Commercial Officer sold 1,513 for 1.60, making the whole transaction’s value amount to 2,421. This particular insider is now the holder of 12,624 in total.
Acorda Therapeutics Inc. (ACOR) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2020, the organization reported -$0.35 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.48) by $0.13. This company achieved a net margin of -141.87 while generating a return on equity of -59.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
Acorda Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 4.70% and is forecasted to reach -1.84 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 29.00% through the next 5 years, which can be compared against the 16.45% growth it accomplished over the previous five years trading on the market.
Acorda Therapeutics Inc. (NASDAQ: ACOR) Trading Performance Indicators
Let’s observe the current performance indicators for Acorda Therapeutics Inc. (ACOR). It’s Quick Ratio in the last reported quarter now stands at 0.90. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.16.
In the same vein, ACOR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.67, a figure that is expected to reach -0.31 in the next quarter, and analysts are predicting that it will be -1.84 at the market close of one year from today.
Technical Analysis of Acorda Therapeutics Inc. (ACOR)
If we take a close look at the recent performances of Acorda Therapeutics Inc. (NASDAQ: ACOR), its last 5-days Average volume was 1.52 million that shows plunge from its year to date volume of 2.14 million. During the previous 9 days, stock’s Stochastic %D was recorded 33.13% While, its Average True Range was 0.0482.
Raw Stochastic average of Acorda Therapeutics Inc. (ACOR) in the period of the previous 100 days is set at 12.56%, which indicates a major fall in contrast to 55.58% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 75.68% that was lower than 88.04% volatility it exhibited in the past 100-days period.